Daily BriefsEquity Bottom-Up

Daily Brief Equity Bottom-Up: [Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook and more

In today’s briefing:

  • [Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook
  • GES: Snapping the Store: Summer Begins to Sizzle; Reiterate Buy, $37 PT
  • [Q2 Earnings Preview] Meta’s Ad Revenues Expected to Surge, But Rising Spend Remains a Concern
  • Yeo Hiap Seng (YHS SP): Healthy Drinks, Thirsty Shareholders
  • Axon: Stunning The Competition – [Business Breakdowns, EP.175]
  • Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion
  • ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’
  • JAKK: 2Q Preview: Setting up for Success; Reiterate Buy Rating, $24 PT
  • Tech Supply Chain Tracker (25-Jul-2024): BOE boosts S. Korean suppliers, Wonik gets more orders
  • Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start


[Earnings Preview] Weak Refining Margins and Gas Prices Dampen Chevron’s Q2 Earnings Outlook

By Suhas Reddy

  • Chevron’s Q2 revenue is set to dip 0.6% YoY, with EPS projected to drop 4.5% YoY on the back of lower refinery margins and natural gas prices.
  • Higher Brent crude prices and strong production may help Chevron partially offset Q2’s challenges.
  • Unplanned downtime at two Australian LNG plants during Q2 raises concerns about a drop in production.

GES: Snapping the Store: Summer Begins to Sizzle; Reiterate Buy, $37 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, $37 price target and projections for Guess?
  • after visiting stores in Long Island and the Metropolitan New York City area.
  • With the return of hot and humid weather, we believe Guess?

[Q2 Earnings Preview] Meta’s Ad Revenues Expected to Surge, But Rising Spend Remains a Concern

By Uttkarsh Kohli

  • Meta is expected to report a 58% YoY increase in EPS to $4.71, with revenue climbing 20% YoY to $38.29B, driven by robust ad performance.
  • Meta plans a 20% cut in Reality Labs’ budget through 2026, aiming to save $3B while shifting focus to upcoming hardware production.
  • In Q1, increased daily active users and a 6% rise in average ad prices have boosted Meta’s ad revenue, despite heightened competition and regulatory pressures. Likely to continue.

Yeo Hiap Seng (YHS SP): Healthy Drinks, Thirsty Shareholders

By Devi Subhakesan

  • Yeo Hiap Seng(YHS SP) , known for its Yeo’s brand of Asian/health drinks, trades near its 52-week low at SGD 0.55, despite having financial assets and cash worth SGD 0.44/share.
  • With limited guidance on reinvestment/growth opportunities and management’s stance against returning cash to shareholders, the stock trades around dividend yield, now at 3.6%.
  • Over the past decade, the stock has lost 75% of its value, and management must take decisive actions to enhance long-term shareholder value.

Axon: Stunning The Competition – [Business Breakdowns, EP.175]

By Business Breakdowns

  • Axon sells a public safety technology ecosystem that includes three main product groups, TASERs, body-worn cameras and other sensors, and evidence software, amongst a host of other software services, including virtual reality training.
  • Axon’s solutions really seek to solve three of the biggest problems facing public safety, too many officers and too many suspects are dying from gunshots.
  • Axon solves for this is as the monopoly provider of TASERs globally. A TASER can be used as an alternative to firearms to temporarily incapacitate a suspect so that they may be restrained with a much, much lower chance of doing physical harm.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Samsung Biologics (207940 KS): Strong 2Q24 Result; Annual Revenue to Surpass KRW4 Trillion

By Tina Banerjee

  • In 2Q24, Samsung Biologics (207940 KS) reported 34% YoY revenue growth to KRW1,157B, driven by full utilization of Plants 1–3, ramp-up of Plant 4, milestone payment, and favorable Fx.
  • The company expects annual revenue to exceed KRW4T mark this year, thereby setting a record for the Korean pharmaceutical and biotechnology sector.
  • During 1H24, Samsung Biologics has secured order worth of KRW2.6T. Currently, the company is serving 16 out of the top 20 global pharmaceutical companies, up from 14 last year.

ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’

By Geoff Howie

  • ESG Brew with ComfortDelGro’s Group Chief Sustainability and Risk Officer: ‘Our transition to cleaner energy vehicles will be a game-changer’ Land transport operator ComfortDelGro is switching its fleet of over 40,000 vehicles in 12 countries to cleaner energy ones as part of its sustainability drive.
  • Jong explains: “We operate in 12 countries with a total fleet of over 40,000 vehicles spanning taxis, buses, trains and more.

JAKK: 2Q Preview: Setting up for Success; Reiterate Buy Rating, $24 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating, projections and $24 price target for JAKKS Pacific with the company announcing 2Q24 (June) results after the close on Wednesday.
  • While we do not expect, nor have we projected, a strong 2Q, we do believe management will be upbeat on a number of key fronts, including: 1) Cleaning up inventory levels in anticipation of Holiday strength and new launches; 2) gearing up for more normalized Halloween costume demand; 3) initial launches for The Simpsons lines to key domestic and international retailers; 4) progress on the international expansion front; 5) the initial shipments for the Authentic Brands partnership and 6) potential demand for Moana 2 and Sonic the Hedgehog 3 Holiday movies.
  • Further, we expect the balance sheet has remained debt free, cash rich and management will provide an update on potential return to shareholders.

Tech Supply Chain Tracker (25-Jul-2024): BOE boosts S. Korean suppliers, Wonik gets more orders

By Tech Supply Chain Tracker

  • BOE’s B16 OLED commitment boosts Korean suppliers, Wonik to see surge in orders
  • Offshore wind delays in Taiwan lead to focus on Japan and Korea for opportunities
  • Onsemi chosen to power VW EV, Elon Musk supports Trump’s EV policies, tariff war on chips impacts consumers and companies

Ainos, Inc. – Veldona Animal Study Enrolls First Subject, Marking a Good Start

By Water Tower Research

  • Enrolled first subject in feline oral disease study, paving way for animal health opportunity.
  • The randomized, double- blind Veldona animal study will enroll 30 cats with feline chronic gingivostomatitis (FCGS) at a single Taiwan clinical site.
  • Two dosage groups, a low dose (6,000 IU) and high dose (12,000 IU), will be evaluated. The first enrolled subject will be dosed later this week. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars